EUVIMEDEUVIMED entdecken
Scoping Review

MEDICATION-RELATED OSTEONECROSIS OF JAWS: A SCOPING REVIEW OF CONTEMPORARY EVIDENCE

V Selva Sigamani, M Surenthar, S K Kamaladharani

International Journal of Drug Delivery Technology · 09.06.2026 · 16 (51s)

DOI: 10.25258/ijddt.16.51s.136 ↗

Kurz gefasst

Scoping Review in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 09.06.2026. Verfasst von V Selva Sigamani und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medication-related osteonecrosis of the jaws (MRONJ), previously termed bisphosphonate-related osteonecrosis of the jaws (BRONJ), represents a debilitating condition characterized by exposed necrotic bone in the maxillofacial region persisting for over eight weeks in patients exposed to antiresorptive or antiangiogenic agents, without a history of jaw radiation. Initially described by Marx in 2003 as osteochemonecrosis in patients receiving bisphosphonates for multiple myeloma and metastatic cancers, its incidence has risen with the ageing population and increased use of these drugs for osteoporosis, bone metastases from breast, prostate, and lung cancers, and other skeletal-related events. Aim of the review was to evaluate the prevalence of MRONJ associated with bisphosphonates, denosumab, and other antiresorptive drugs, and synthesize current evidence on its etiology, clinical outcomes, and preventive strategies by searching PubMed, MEDLINE, Scopus, Web of Science, and Google Scholar from January 2014 to January 2026. Inclusion criteria encompassed original research (RCTs, observational studies) on MRONJ induced by bisphosphonates, denosumab, RANK-L inhibitors, VEGF inhibitors, in patients treated for both primary and secondary cancer or osteoporosis. Exclusions were case reports, case series, in vitro studies, and conference proceedings. Following duplicate removal, two reviewers independently screened titles/abstracts/full texts using Covidence software, with any discrepancies resolved by a third reviewer. Data relating to study design, population, interventions, and key outcomes (prevalence, pain, and functional status) were extracted. Risk of bias was evaluated using RevMan 5.2.0 for randomized controlled trials and ROBINS-I for non-randomized studies. Owing to substantial heterogeneity among studies, meta-analysis was precluded, and findings were synthesized narratively. From 7242 articles, 4 studies (6,761 participants) were included, primarily involving bisphosphonates (n=108) for breast cancer, multiple myeloma, and osteoporosis, and denosumab (n=6653). Bisphosphonates showed higher MRONJ incidence than other agents, with mandibular predominance, elderly females most affected, and elevated risk from intravenous administration. Denosumab exhibited higher MRONJ rates than zoledronic acid (3.2% vs. 2.3% over 3 years). Histopathological examination revealed osteoclast hyperactivity and increased multinucleation. Tooth extractions were found to act as precipitating factors in the onset of cases. According to a recent AAOMS position paper from 2022, it is advised to observe a drug holiday for three months prior to the dental procedure. Therefore, before starting anti-resorptive therapy, clinicians should be aware of risk factors and encourage preventive measures like thorough oral examinations with appropriate radiographs, oral hygiene instructions, and completion of necessary dental treatments. Low-moderate bias prevailed. Bisphosphonates pose the greatest MRONJ risk among antiresorptives, especially intravenously; prevention demands pre-treatment dental evaluation, drug holidays, and multidisciplinary care. Enhanced clinician awareness is crucial to mitigate this underrated entity.

Zitieren

APA

Sigamani, V. S., Surenthar, M., & Kamaladharani, S. K. (2026). MEDICATION-RELATED OSTEONECROSIS OF JAWS: A SCOPING REVIEW OF CONTEMPORARY EVIDENCE. International Journal of Drug Delivery Technology, 16(51s). https://doi.org/10.25258/ijddt.16.51s.136

Vancouver

Sigamani VS, Surenthar M, Kamaladharani SK. MEDICATION-RELATED OSTEONECROSIS OF JAWS: A SCOPING REVIEW OF CONTEMPORARY EVIDENCE. International Journal of Drug Delivery Technology. 2026;16(51s). doi:10.25258/ijddt.16.51s.136

BibTeX
@article{Sigamani2026,
  author = {Sigamani, V Selva and Surenthar, M and Kamaladharani, S K},
  title = {MEDICATION-RELATED OSTEONECROSIS OF JAWS: A SCOPING REVIEW OF CONTEMPORARY EVIDENCE},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {51s},
  doi = {10.25258/ijddt.16.51s.136}
}
Kostenlos starten →